Cargando…

Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance

PURPOSE: To report visual outcomes and rate of retinal pigment epithelium (RPE) atrophy progression in patients with extensive macular atrophy with pseudodrusen-like appearance (EMAP). DESIGN: Retrospective, observational study. PARTICIPANTS: Patients with EMAP and symptom onset before 55 years of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Romano, Francesco, Airaldi, Matteo, Cozzi, Mariano, Oldani, Marta, Riva, Ester, Bertoni, Alice Ingrid, Dautaj, Astrit, Bertelli, Matteo, Staurenghi, Giovanni, Salvetti, Anna Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559088/
https://www.ncbi.nlm.nih.gov/pubmed/36246010
http://dx.doi.org/10.1016/j.xops.2021.100016
_version_ 1784807584625065984
author Romano, Francesco
Airaldi, Matteo
Cozzi, Mariano
Oldani, Marta
Riva, Ester
Bertoni, Alice Ingrid
Dautaj, Astrit
Bertelli, Matteo
Staurenghi, Giovanni
Salvetti, Anna Paola
author_facet Romano, Francesco
Airaldi, Matteo
Cozzi, Mariano
Oldani, Marta
Riva, Ester
Bertoni, Alice Ingrid
Dautaj, Astrit
Bertelli, Matteo
Staurenghi, Giovanni
Salvetti, Anna Paola
author_sort Romano, Francesco
collection PubMed
description PURPOSE: To report visual outcomes and rate of retinal pigment epithelium (RPE) atrophy progression in patients with extensive macular atrophy with pseudodrusen-like appearance (EMAP). DESIGN: Retrospective, observational study. PARTICIPANTS: Patients with EMAP and symptom onset before 55 years of age, at least 12 months of follow-up using Spectralis blue-light fundus autofluorescence (BAF) and OCT and with no other ocular or systemic conditions. METHODS: Best-corrected visual acuity (BCVA), BAF, and OCT images were reviewed at baseline and at each annual visit until the last available follow-up. Atrophy was measured by 2 graders using the region finder software on Heidelberg Explorer and confirmed using OCT scans covering the entire atrophic lesion. The following imaging biomarkers were analyzed at each visit: foveal atrophy, vitreomacular traction, outer retinal tubulations, choroidal caverns and subfoveal choroidal thickness, border autofluorescence pattern (hyper-autofluorescent or iso-autofluorescent), and border irregularity as expressed by circularity index (CI). MAIN OUTCOME MEASURES: Primary outcomes were annual rate of atrophy enlargement and BCVA loss in EMAP patients. Secondary outcomes included the assessment of potential factors able to predict disease progression. RESULTS: Thirty-six eyes from 18 patients with EMAP (6 men [33%]; mean age at symptom onset, 48.1 ± 1.7 years) were included. Mean follow-up lasted 32.8 ± 14.3 months. RPE atrophy increased from 10.8 ± 6.3 mm(2) at baseline to 18.1 ± 8.3 mm(2) at the end of follow-up, with a rate of 2.91 ± 1.09 mm(2)/year. Faster progression was associated with smaller CI at baseline (P = 0.02) and with iso-autofluorescent lesion borders (P = 0.01). Visual acuity declined progressively at a rate of 7.4 ± 5.8 letters per year, with 57% of eyes showing vision of 20/200 Snellen or worse at the 4-year follow-up. Worse visual outcomes were observed in patients with early foveal involvement at baseline (P = 0.02). CONCLUSIONS: Patients affected by EMAP present a rapid expansion of RPE atrophy that is comparable with the diffuse-trickling form of geographic atrophy. More irregular and iso-autofluorescent lesion borders seem to predict faster progression. Our findings may provide relevant information for patient counseling and future interventional approaches to select the best candidates and proper clinical outcomes.
format Online
Article
Text
id pubmed-9559088
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95590882022-10-14 Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance Romano, Francesco Airaldi, Matteo Cozzi, Mariano Oldani, Marta Riva, Ester Bertoni, Alice Ingrid Dautaj, Astrit Bertelli, Matteo Staurenghi, Giovanni Salvetti, Anna Paola Ophthalmol Sci Original Article PURPOSE: To report visual outcomes and rate of retinal pigment epithelium (RPE) atrophy progression in patients with extensive macular atrophy with pseudodrusen-like appearance (EMAP). DESIGN: Retrospective, observational study. PARTICIPANTS: Patients with EMAP and symptom onset before 55 years of age, at least 12 months of follow-up using Spectralis blue-light fundus autofluorescence (BAF) and OCT and with no other ocular or systemic conditions. METHODS: Best-corrected visual acuity (BCVA), BAF, and OCT images were reviewed at baseline and at each annual visit until the last available follow-up. Atrophy was measured by 2 graders using the region finder software on Heidelberg Explorer and confirmed using OCT scans covering the entire atrophic lesion. The following imaging biomarkers were analyzed at each visit: foveal atrophy, vitreomacular traction, outer retinal tubulations, choroidal caverns and subfoveal choroidal thickness, border autofluorescence pattern (hyper-autofluorescent or iso-autofluorescent), and border irregularity as expressed by circularity index (CI). MAIN OUTCOME MEASURES: Primary outcomes were annual rate of atrophy enlargement and BCVA loss in EMAP patients. Secondary outcomes included the assessment of potential factors able to predict disease progression. RESULTS: Thirty-six eyes from 18 patients with EMAP (6 men [33%]; mean age at symptom onset, 48.1 ± 1.7 years) were included. Mean follow-up lasted 32.8 ± 14.3 months. RPE atrophy increased from 10.8 ± 6.3 mm(2) at baseline to 18.1 ± 8.3 mm(2) at the end of follow-up, with a rate of 2.91 ± 1.09 mm(2)/year. Faster progression was associated with smaller CI at baseline (P = 0.02) and with iso-autofluorescent lesion borders (P = 0.01). Visual acuity declined progressively at a rate of 7.4 ± 5.8 letters per year, with 57% of eyes showing vision of 20/200 Snellen or worse at the 4-year follow-up. Worse visual outcomes were observed in patients with early foveal involvement at baseline (P = 0.02). CONCLUSIONS: Patients affected by EMAP present a rapid expansion of RPE atrophy that is comparable with the diffuse-trickling form of geographic atrophy. More irregular and iso-autofluorescent lesion borders seem to predict faster progression. Our findings may provide relevant information for patient counseling and future interventional approaches to select the best candidates and proper clinical outcomes. Elsevier 2021-03-19 /pmc/articles/PMC9559088/ /pubmed/36246010 http://dx.doi.org/10.1016/j.xops.2021.100016 Text en © 2021 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Romano, Francesco
Airaldi, Matteo
Cozzi, Mariano
Oldani, Marta
Riva, Ester
Bertoni, Alice Ingrid
Dautaj, Astrit
Bertelli, Matteo
Staurenghi, Giovanni
Salvetti, Anna Paola
Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance
title Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance
title_full Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance
title_fullStr Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance
title_full_unstemmed Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance
title_short Progression of Atrophy and Visual Outcomes in Extensive Macular Atrophy with Pseudodrusen-like Appearance
title_sort progression of atrophy and visual outcomes in extensive macular atrophy with pseudodrusen-like appearance
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559088/
https://www.ncbi.nlm.nih.gov/pubmed/36246010
http://dx.doi.org/10.1016/j.xops.2021.100016
work_keys_str_mv AT romanofrancesco progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT airaldimatteo progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT cozzimariano progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT oldanimarta progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT rivaester progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT bertonialiceingrid progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT dautajastrit progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT bertellimatteo progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT staurenghigiovanni progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance
AT salvettiannapaola progressionofatrophyandvisualoutcomesinextensivemacularatrophywithpseudodrusenlikeappearance